Skip to main content

Advertisement

SpringerLink
Log in

Aspirin dosing in cardiovascular disease prevention and management: an update

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. Clinical and epidemiological literature suggests that while net benefits of aspirin in primary prevention of CVDs are less clear, the benefits of aspirin in acute scenarios and secondary prevention settings are well established. However, its optimum dosing requirements have been up for debate especially in various settings of acute coronary syndrome and stable ischemic heart disease. The role of clinician in stratifying individual risk score to achieve net clinical benefit is an important determinant of initiating aspirin therapy. The purpose of this article is to review association of aspirin and CVD in general, and to review its dosing regimens in acute settings as well as primary and secondary prevention as suggested by various established guidelines. We also aim to provide the readers an update on recent changes and current evidence based practice trends.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. http://www.cdc.gov/heartdisease/facts.htm. Accessed 07/05/2015

  2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB (2015) Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131(4):e29–e322

    Article  PubMed  Google Scholar 

  3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123(8):933–944

    Article  PubMed  Google Scholar 

  4. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI (2006) Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 31(1):52–61

    Article  PubMed  Google Scholar 

  5. http://millionhearts.hhs.gov/aboutmh/overview.html. Accessed 07/05/2015

  6. https://en.wikipedia.org/?title=Aspirin. Accessed 07/05/2015

  7. Norn S, Permin H, Kruse PR, Kruse E (2009) From willow bark to acetylsalicylic acid. Dan Medicinhist Arbog 37:79–98

    PubMed  Google Scholar 

  8. http://www.medicalnewstoday.com/articles/161255.php. Accessed 07/05/2015

  9. Lafont O (1996) Clarification on publications concerning the synthesis of acetylsalicylic acid. Rev Hist Pharm (Paris) 43(310):269–273

    Article  CAS  Google Scholar 

  10. Sneader W (2000) The discovery of aspirin: a reappraisal. BMJ 321(7276):1591–1594

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Miner J, Hoffhines A (2007) The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J 34(2):179–186

    PubMed Central  PubMed  Google Scholar 

  12. Craven LL (1950) Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 4(2):95

    CAS  PubMed  Google Scholar 

  13. Craven LL (1953) Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 75(1):38–44

    CAS  PubMed  Google Scholar 

  14. http://www.jameslindlibrary.org/boston-collaborative-drug-surveillance-group-1974/. Accessed 07/05/2015

  15. Fuster V, Sweeny JM (2011) Aspirin: a historical and contemporary therapeutic overview. Circulation 123(7):768–778

    Article  PubMed  Google Scholar 

  16. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25):232–235

    Article  CAS  PubMed  Google Scholar 

  17. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5–6):255–258

    Article  CAS  PubMed  Google Scholar 

  18. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1982/. Accessed 07/05/2015

  19. Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101(10):1206–1218

    Article  CAS  PubMed  Google Scholar 

  20. Casado-Arroyo R, Sostres C, Lanas A (2013) Optimizing the use of aspirin for cardiovascular prevention. Drugs 73(8):803–814

    Article  CAS  PubMed  Google Scholar 

  21. Lopez-Farre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S (1995) Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 91(7):2080–2088

    Article  CAS  PubMed  Google Scholar 

  22. Bolz SS, Pohl U (1997) Indomethacin enhances endothelial NO release—evidence for a role of PGI2 in the autocrine control of calcium-dependent autacoid production. Cardiovasc Res 36(3):437–444

    Article  CAS  PubMed  Google Scholar 

  23. Steer KA, Wallace TM, Bolton CH, Hartog M (1997) Aspirin protects low density lipoprotein from oxidative modification. Heart 77(4):333–337

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA (1998) Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97(8):716–720

    Article  CAS  PubMed  Google Scholar 

  25. http://www.uptodate.com/contents/aspirin-mechanism-of-action-major-toxicities-and-use-in-rheumatic-diseases?source=search_result&search=aspirin+mechanism+of+action&selectedTitle=1%7E150. Accessed 07/05/2015

  26. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N (2014) Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312(23):2510–2520

    Article  PubMed  Google Scholar 

  27. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295(3):306–313

    Article  CAS  PubMed  Google Scholar 

  28. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A (2009) Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339:b4531

    Article  PubMed Central  PubMed  Google Scholar 

  29. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293–1304

    Article  CAS  PubMed  Google Scholar 

  30. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK (2012) Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 172(3):209–216

    Article  CAS  PubMed  Google Scholar 

  31. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860

    Article  PubMed  Google Scholar 

  32. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S et al (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296(6618):313–316

    Article  CAS  Google Scholar 

  33. The Medical Research Council’s General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351(9098):233–241

    Article  Google Scholar 

  34. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701

    Article  CAS  PubMed  Google Scholar 

  35. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 28(19):2375–2414

    Article  PubMed  Google Scholar 

  36. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm. Accessed 07/05/2015

  37. U.S. Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136(2):157–160

    Article  Google Scholar 

  38. Calonge N, Petitti DB, DeWitt TG, Gordis L, Gregory KD, Harris R, Isham G, LeFevre ML, Loveland-Cherry C, Marion LN, Moyer VA, Ockene JK, Sawaya GF, Siu AL, Teutsch SM, Yawn BP (2009) Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150(6):396–404

    Article  Google Scholar 

  39. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106(3):388–391

    Article  PubMed  Google Scholar 

  40. Patrono C (2013) Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart J 34(44):3403–3411

    Article  CAS  PubMed  Google Scholar 

  41. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA (2012) Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e637S–668S

    PubMed Central  CAS  PubMed  Google Scholar 

  42. http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf. Accessed 07/05/2015

  43. Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Theroux P, Turpie AG, Welsh RC, Tanguay JF (2011) The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 27(2):208–221

    Article  CAS  PubMed  Google Scholar 

  44. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, Grove A, Gurung B, Morrow S, Stranges S, Clarke A (2013) Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One 8(12):e81970

    Article  PubMed Central  PubMed  Google Scholar 

  45. Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR (2012) Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy 32(11):1020–1035

    Article  PubMed  Google Scholar 

  46. Mainous AG, Tanner RJ, Shorr RI, Limacher MC (2014) Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J Am Heart Assoc 3(4):e000989. doi:10.1161/JAHA.114.000989

  47. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH (2006) Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 30(1):74–77

    Article  PubMed  Google Scholar 

  48. Miser WF (2011) Appropriate aspirin use for primary prevention of cardiovascular disease. Am Fam Phys 83(12):1380–1386

    Google Scholar 

  49. The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719):827–830

    Article  Google Scholar 

  50. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921):81–106

    Article  Google Scholar 

  51. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316(7141):1337–1343

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. El-Menyar A, AlHabib KF, Al-Motarreb A, Hersi A, Al Faleh H, Asaad N, Al Saif S, Almahmeed W, Sulaiman K, Amin H, Al-Lawati J, Alsheikh-Ali AA, AlQahtani A, Al-Sagheer NQ, Singh R, Al Suwaidi J (2012) Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes. Am J Cardiovasc Drugs 12(2):127–135

    Article  CAS  PubMed  Google Scholar 

  53. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748):1233–1243

    Article  CAS  PubMed  Google Scholar 

  54. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349(9065):1569–1581

    Article  Google Scholar 

  55. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349(9066):1641–1649

    Article  Google Scholar 

  56. Campbell CL, Smyth S, Montalescot G, Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297(18):2018–2024

    Article  CAS  PubMed  Google Scholar 

  57. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ (2005) Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95(10):1218–1222

    Article  CAS  PubMed  Google Scholar 

  58. Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130(3 Pt 1):465–472

    Article  CAS  PubMed  Google Scholar 

  59. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69(6):1366–1372

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Dalen JE (2006) Aspirin to prevent heart attack and stroke: what’s the right dose? Am J Med 119(3):198–202

    Article  CAS  PubMed  Google Scholar 

  61. Bem D, Dretzke J, Stevens S, Lordkipanidze M, Hodgkinson J, Bayliss S, Moore D, Fitzmaurice D (2015) Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Syst Rev 4(1):88

  62. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86

    Article  Google Scholar 

  63. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Morais J, Deckers J, Ferreira R, Mazzotta G, Steg PG, Teixeira F, Wilcox R (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25(2):166–181

  64. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol 58(24):e44–122

    Article  PubMed  Google Scholar 

  65. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ (2014) AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 64(24):e139–228

    Article  PubMed  Google Scholar 

  66. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW (2013) ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61(4):e78–140

    Article  PubMed  Google Scholar 

  67. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB III, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV (2012) ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60(24):e44–e164

    Article  PubMed  Google Scholar 

  68. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45(7):2160–2236

    Article  PubMed  Google Scholar 

  69. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ‘t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569–2619

    Article  CAS  PubMed  Google Scholar 

  70. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999–3054

    Article  PubMed  Google Scholar 

  71. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541–2619

    Article  PubMed  Google Scholar 

  72. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34(38):2949–3003

    Article  PubMed  Google Scholar 

  73. http://www.uptodate.com/contents/antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes?source=search_result&search=aspirin+and+stemi&selectedTitle=5%7E150. Accessed 07/05/2015

  74. http://www.uptodate.com/contents/antiplatelet-agents-in-acute-st-elevation-myocardial-infarction?source=search_result&search=aspirin+and+stemi&selectedTitle=1%7E150. Accessed 07/05/2015

  75. http://www.uptodate.com/contents/antiplatelet-therapy-after-coronary-artery-stenting?source=search_result&search=antiplatelet+agents&selectedTitle=3%7E150. Accessed 07/05/2015

  76. http://www.uptodate.com/contents/antiplatelet-therapy-for-secondary-prevention-of-stroke?source=search_result&search=antiplatelet+agents&selectedTitle=2%7E150. Accessed 07/05/2015

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, 231 Albert Sabin Way, MLC 0542, Cincinnati, OH, 45267-0542, USA

    Leila Ganjehei & Richard C. Becker

  2. Lung and Vascular Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA

    Richard C. Becker

Authors
  1. Leila Ganjehei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard C. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leila Ganjehei.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ganjehei, L., Becker, R.C. Aspirin dosing in cardiovascular disease prevention and management: an update. J Thromb Thrombolysis 40, 499–511 (2015). https://doi.org/10.1007/s11239-015-1267-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1267-6

Keywords

Search

Navigation